NCT02853903View on ClinicalTrials.gov

Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

July 1, 2019

Conditions
Malignant Solid Tumour
Interventions
BIOLOGICAL

NK immunotherapy

Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.

Trial Locations (1)

510665

Fuda cancer institute of Fuda cancer hospital, Guangzhou

All Listed Sponsors
collaborator

Shenzhen Hank Bioengineering Institute

OTHER

lead

Fuda Cancer Hospital, Guangzhou

OTHER

NCT02853903 - Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors | Biotech Hunter | Biotech Hunter